Deciphera Pharmaceuticals, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 42 rows in 2021. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2021-12-15: Reporting owner Kelly Thomas Patrick; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2021-12-15: Reporting owner Pitman Jama; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2021-12-15: Reporting owner Hoerter Steven L.; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2021-12-15: Reporting owner Sherman Matthew L; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2021-12-15 | Kelly Thomas Patrick Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +82,265 82,265 owned after | $9.23 exercise price | 2021-12-17 | |
| 2021-12-15 | Pitman Jama Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +62,971 62,971 owned after | $9.23 exercise price | 2021-12-17 | |
| 2021-12-15 | Hoerter Steven L. Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +270,357 270,357 owned after | $9.23 exercise price | 2021-12-17 | |
| 2021-12-15 | Sherman Matthew L Officer (EVP & Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +82,265 82,265 owned after | $9.23 exercise price | 2021-12-17 | |
| 2021-12-15 | Flynn Daniel Lee Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +82,265 82,265 owned after | $9.23 exercise price | 2021-12-17 | |
| 2021-12-15 | Martin Daniel C. Officer (Chief Commercial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +62,971 62,971 owned after | $9.23 exercise price | 2021-12-17 | |
| 2021-06-23 | Walsh Dennis Leo Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $35.86 exercise price | 2021-06-25 | |
| 2021-06-23 | Friedman Franklin Stuart Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $35.86 exercise price | 2021-06-25 | |
| 2021-06-23 | Bristol James Arthur Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $35.86 exercise price | 2021-06-25 | |
| 2021-06-23 | Martin John Richard Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $35.86 exercise price | 2021-06-25 | |
| 2021-06-23 | Squarer Ron Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $35.86 exercise price | 2021-06-25 | |
| 2021-06-23 | Benz Edward J. JR Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $35.86 exercise price | 2021-06-25 | |
| 2021-06-23 | Kelley Susan L. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $35.86 exercise price | 2021-06-25 | |
| 2021-06-23 | Allen Patricia L Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +12,000 12,000 owned after | $35.86 exercise price | 2021-06-25 | |
| 2021-05-03 | Taylor Michael Douglas Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,354 0 owned after | $1.89 exercise price | 2021-05-05 | |
| 2021-05-03 | Taylor Michael Douglas Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,646 193,752 owned after | $3.95 exercise price | 2021-05-05 | |
| 2021-04-20 | Bristol James Arthur Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,700 22,150 owned after | $3.95 exercise price | 2021-04-21 | |
| 2021-04-19 | Bristol James Arthur Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,300 23,850 owned after | $3.95 exercise price | 2021-04-21 | |
| 2021-04-12 | Bristol James Arthur Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −14,700 29,150 owned after | $3.95 exercise price | 2021-04-14 | |
| 2021-04-02 holding as of filing | Pitman Jama Officer (SVP, Regulatory & Quality) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $6.13 exercise price | 2021-04-02 | ||
| 2021-04-02 holding as of filing | Pitman Jama Officer (SVP, Regulatory & Quality) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $17.00 exercise price | 2021-04-02 | ||
| 2021-04-02 holding as of filing | Pitman Jama Officer (SVP, Regulatory & Quality) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $29.71 exercise price | 2021-04-02 | ||
| 2021-04-02 holding as of filing | Pitman Jama Officer (SVP, Regulatory & Quality) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $26.35 exercise price | 2021-04-02 | ||
| 2021-04-02 holding as of filing | Pitman Jama Officer (SVP, Regulatory & Quality) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $54.87 exercise price | 2021-04-02 | ||
| 2021-04-02 holding as of filing | Pitman Jama Officer (SVP, Regulatory & Quality) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $47.49 exercise price | 2021-04-02 | ||
| 2021-04-02 holding as of filing | Martin Daniel C. Officer (Chief Commercial Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $36.10 exercise price | 2021-04-02 | ||
| 2021-04-02 holding as of filing | Martin Daniel C. Officer (Chief Commercial Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $26.35 exercise price | 2021-04-02 | ||
| 2021-04-02 holding as of filing | Martin Daniel C. Officer (Chief Commercial Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $54.87 exercise price | 2021-04-02 | ||
| 2021-04-02 holding as of filing | Martin Daniel C. Officer (Chief Commercial Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $47.79 exercise price | 2021-04-02 | ||
| 2021-04-01 | Taylor Michael Douglas Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −8,000 2,354 owned after | $1.89 exercise price | 2021-04-06 | |
| 2021-03-01 | Taylor Michael Douglas Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −8,000 10,354 owned after | $1.89 exercise price | 2021-03-03 | |
| 2021-02-16 | Kelly Thomas Patrick Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +49,900 49,900 owned after | $47.79 exercise price | 2021-02-18 | |
| 2021-02-16 | Flynn Daniel Lee Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +49,900 49,900 owned after | $47.79 exercise price | 2021-02-18 | |
| 2021-02-16 | Sherman Matthew L Officer (EVP & Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +49,900 49,900 owned after | $47.79 exercise price | 2021-02-18 | |
| 2021-02-16 | Hoerter Steven L. Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | −210,000 210,000 owned after | $47.79 exercise price | 2021-02-18 | |
| 2021-02-01 | Taylor Michael Douglas Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −8,000 18,354 owned after | $1.89 exercise price | 2021-02-03 | |
| 2021-01-21 | Hoerter Steven L. Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,078 395,735 owned after | $25.40 exercise price | 2021-01-25 | |
| 2021-01-15 | Friedman Franklin Stuart Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,563 1,563 owned after | $31.99 | 2021-01-20 | |
| 2021-01-15 | Walsh Dennis Leo Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,563 1,563 owned after | $31.99 | 2021-01-20 | |
| 2021-01-15 | Bristol James Arthur Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,000 43,850 owned after | $3.95 exercise price | 2021-01-20 | |
| 2021-01-15 | Squarer Ron Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +1,563 1,563 owned after | $31.99 | 2021-01-20 | |
| 2021-01-04 | Taylor Michael Douglas Director | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −19,000 26,354 owned after | $1.89 exercise price | 2021-01-06 |